Nanoplasmonics-enhanced label-free imaging of endothelial cell monolayer integrity.


Journal

Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289

Informations de publication

Date de publication:
15 Sep 2019
Historique:
received: 25 03 2019
revised: 21 06 2019
accepted: 24 06 2019
pubmed: 8 7 2019
medline: 23 1 2020
entrez: 8 7 2019
Statut: ppublish

Résumé

Surface plasmon resonance imaging (SPRI) is a powerful label-free imaging modality for the analysis of morphological dynamics in cell monolayers. However, classical plasmonic imaging systems have relatively poor spatial resolution along one axis due to the plasmon mode attenuation distance (tens of μm, typically), which significantly limits their ability to resolve subcellular structures. We address this limitation by adding an array of nanostructures onto the metal sensing surface (25 nm thick, 200 nm width, 400 nm period grating) to couple localized plasmons with propagating plasmons, thereby reducing attenuation length and commensurately increasing spatial imaging resolution, without significant loss of sensitivity or image contrast. In this work, experimental results obtained with both conventional unstructured and nanostructured gold film SPRI sensor chips show a clear gain in spatial resolution achieved with surface nanostructuring. The work demonstrates the ability of the nanostructured SPRI chips to resolve fine morphological detail (intercellular gaps) in experiments monitoring changes in endothelial cell monolayer integrity following the activation of the cell surface protease-activated receptor 1 (PAR1) by thrombin. In particular, the nanostructured chips reveal the persistence of small intercellular gaps (<5 μm

Identifiants

pubmed: 31280004
pii: S0956-5663(19)30557-3
doi: 10.1016/j.bios.2019.111478
pii:
doi:

Substances chimiques

Gold 7440-57-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111478

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Frederic A Banville (FA)

Laboratoire Nanotechnologies Nanosystèmes (LN2), CNRS UMI-3463, Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Institut Interdisciplinaire d'Innovation Technologique (3IT), Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Laboratoire Charles Fabry (LCF), Institut d'Optique Graduate School, Université Paris-Saclay, CNRS, Palaiseau, 91127, France.

Julien Moreau (J)

Laboratoire Charles Fabry (LCF), Institut d'Optique Graduate School, Université Paris-Saclay, CNRS, Palaiseau, 91127, France.

Kevin Chabot (K)

Laboratoire Nanotechnologies Nanosystèmes (LN2), CNRS UMI-3463, Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Institut Interdisciplinaire d'Innovation Technologique (3IT), Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada.

Andrea Cattoni (A)

Centre de Nanosciences et de Nanotechnologies (C2N), CNRS UMR-9001, Université Paris-Sud/Paris-Saclay, Palaiseau, 91120, France.

Ulrike Fröhlich (U)

Département de Pharmacologie et Physiologie, Institut de Pharmacologie de Sherbrooke (IPS), Université de Sherbrooke, Canada.

Jean-François Bryche (JF)

Laboratoire Nanotechnologies Nanosystèmes (LN2), CNRS UMI-3463, Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Institut Interdisciplinaire d'Innovation Technologique (3IT), Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada.

Stéphane Collin (S)

Centre de Nanosciences et de Nanotechnologies (C2N), CNRS UMR-9001, Université Paris-Sud/Paris-Saclay, Palaiseau, 91120, France.

Paul G Charette (PG)

Laboratoire Nanotechnologies Nanosystèmes (LN2), CNRS UMI-3463, Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Institut Interdisciplinaire d'Innovation Technologique (3IT), Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada.

Michel Grandbois (M)

Laboratoire Nanotechnologies Nanosystèmes (LN2), CNRS UMI-3463, Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Département de Pharmacologie et Physiologie, Institut de Pharmacologie de Sherbrooke (IPS), Université de Sherbrooke, Canada.

Michael Canva (M)

Laboratoire Nanotechnologies Nanosystèmes (LN2), CNRS UMI-3463, Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Institut Interdisciplinaire d'Innovation Technologique (3IT), Université de Sherbrooke, Sherbrooke, J1K 0A5, Canada; Laboratoire Charles Fabry (LCF), Institut d'Optique Graduate School, Université Paris-Saclay, CNRS, Palaiseau, 91127, France. Electronic address: michael.canva@usherbrooke.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH